Sicen Lin
机构：Shenyang Pharmaceutical University
发表论文 3 篇 · 总被引 66 次 · h-index 3
代表论文
- Oral Microto-Nano Genome-Editing System Enabling Targeted Delivery and Conditional Activation of CRISPR-Cas9 for Gene Therapy of Inflammatory Bowel Disease (2024 · ACS Nano · 被引 42)
- Bacteria-driven bio-therapy: From fundamental studies to clinical trials (2022 · Nano Today · 被引 20)
- Bimetallic nanodot-adenovirus chimera for cancer theranostics via cooperativity of autophagy and ferroptosis (2024 · Cell Reports Physical Science · 被引 3)